CYCLACEL PHARMACEUTICALS INC (CYCC)
US23254L8019 - Common Stock
We assign a fundamental rating of 2 out of 10 to CYCC. CYCC was compared to 565 industry peers in the Biotechnology industry. CYCC has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CYCC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CYCC has reported negative net income.
In the past year CYCC has reported a negative cash flow from operations.
In the past 5 years CYCC always reported negative net income.
CYCC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CYCC has a worse Return On Assets (-250.53%) than 92.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -250.53% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CYCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCC has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CYCC has more shares outstanding
CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -123.20, we must say that CYCC is in the distress zone and has some risk of bankruptcy.
CYCC's Altman-Z score of -123.20 is on the low side compared to the rest of the industry. CYCC is outperformed by 98.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -123.2 |
ROIC/WACCN/A
WACC10.91%
2.3 Liquidity
A Current Ratio of 0.77 indicates that CYCC may have some problems paying its short term obligations.
CYCC has a worse Current ratio (0.77) than 90.21% of its industry peers.
A Quick Ratio of 0.77 indicates that CYCC may have some problems paying its short term obligations.
CYCC's Quick ratio of 0.77 is on the low side compared to the rest of the industry. CYCC is outperformed by 90.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 68.67% over the past year.
The Revenue for CYCC has decreased by -80.83% in the past year. This is quite bad
CYCC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.87% yearly.
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
3.2 Future
Based on estimates for the next years, CYCC will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.14% on average per year.
Based on estimates for the next years, CYCC will show a very strong growth in Revenue. The Revenue will grow by 213.65% on average per year.
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CYCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CYCC's earnings are expected to grow with 25.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.85%
EPS Next 3Y25.1%
5. Dividend
5.1 Amount
CYCC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYCLACEL PHARMACEUTICALS INC
NASDAQ:CYCC (12/23/2024, 11:14:18 AM)
0.3268
+0.01 (+2.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.63%
Inst Owner Change-7.09%
Ins Owners2.48%
Ins Owner Change0%
Market Cap2.06M
Analysts43.33
Price Target1.02 (212.12%)
Short Float %3.03%
Short Ratio0.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)-38.18%
DP-0.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.51%
Min EPS beat(2)50.81%
Max EPS beat(2)68.2%
EPS beat(4)3
Avg EPS beat(4)42.12%
Min EPS beat(4)-3.64%
Max EPS beat(4)68.2%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)9
Avg EPS beat(12)22.73%
EPS beat(16)10
Avg EPS beat(16)7.81%
Revenue beat(2)1
Avg Revenue beat(2)4.58%
Min Revenue beat(2)-86.93%
Max Revenue beat(2)96.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-90.91%
PT rev (3m)-90.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)88.8%
EPS NY rev (1m)37.7%
EPS NY rev (3m)37.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)23.26%
Revenue NY rev (3m)23.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 27.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.4
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.01
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -250.53% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | -123.2 |
F-Score2
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)42.56%
Cap/Depr(5y)135.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%
EBIT growth 1Y46.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.83%
OCF growth 3YN/A
OCF growth 5YN/A